FDA Has “Issues” With NDAs; Half Of 74-Day Letters Note Application Flaws
Executive Summary
About half of the 74-day "issue" letters sent by FDA to NDA applicants in the first six months of the agency's 2003 fiscal year have noted application flaws, Office of New Drugs Director John Jenkins, MD, said at Temple University's annual industry/FDA conference in Philadelphia April 15
You may also be interested in...
User Fee Hike Will Give Sponsors Clarity On Label, Postmarketing Discussions
As part of its recommendations for the renewal of the user fee program, FDA is proposing refinements to its "74-day letters" to give sponsors a more detailed schedule of how the application review will proceed
User Fee Hike Will Give Sponsors Clarity On Label, Postmarketing Discussions
As part of its recommendations for the renewal of the user fee program, FDA is proposing refinements to its "74-day letters" to give sponsors a more detailed schedule of how the application review will proceed
FDA Finalizing Review Principles Guidance; Complete Submissions Urged
FDA's guidance on good review management principles is entering the final clearance stage, Office of New Drugs Director John Jenkins, MD, said during the Drug Information Association annual meeting in Washington, D.C. June 16